摘要
胆囊癌(GBC)是胆道系统最常见的恶性肿瘤,具有高度侵袭性和不良预后特征。由于其发病隐匿,多数患者确诊时已处于中晚期阶段,手术切除机会少。文章总结当前GBC靶向治疗的研究进展,关注关键信号通路相关靶点,ErbB受体、VEGF/VEGFR通路、MAPK通路以及PI3K/Akt/mTOR通路。临床实践显示,部分靶向药物在临床试验中表现出一定疗效,但在应用过程中仍受限于肿瘤异质性、耐药性分子机制以及检测技术瓶颈。生物信息学方法鉴定了PTBP3、WEE1等新兴潜在靶点及其候选药物,这些尚处基础研究阶段。因而,GBC仍面临诸多挑战,未来研究需聚焦于多组学技术整合、联合治疗方案优化、高敏检测方法创新及国际多中心协作,以推动治疗突破。
Gallbladder cancer(GBC)is the most common malignant tumor of the biliary system,with a highly aggressive and poor prognosis profile.Due to its insidious onset,most patients are already in the middle or late stages at the time of diagnosis,and have few opportunities for surgical resection.This article summarizes the current research of targeted therapy for GBC,foucsing on the key signaling pathways-related targets,such as the ErbB receptor,VEGF/VEGFR pathway,MAPK pathway,and PI3K/Akt/mTOR pathway.Some targeted drugs have shown certain efficacy in clinical trials,but there are still problems such as tumor heterogeneity,molecular mechanism of drug resistance,and detection techniques bottleneck.Bioinformatics methods have identified emerging potential targets and their drug candidates such as PTBP3 and WEE1,which are still in the basic research stage.Therefore,GBC still faces many challenges,and future research needs to focus on the integration of multi-omics technology,the optimization of combination treatment regimens,the innovation of high-sensitivity detection methods,and international multi-center collaboration to promote therapeutic breakthroughs.
作者
徐家恒
任超胜
胡彬
周玮洋
李小丹
于照祥
XU Jiaheng;REN Chaosheng;HU Bin;ZHOU Weiyang;LI Xiaodan;YU Zhaoxiang(Department of General Surgery,The First Affiliated Hospital of Xi'an Medical University,Xi'an 710082,China)
出处
《中国肿瘤外科杂志》
2025年第4期409-416,共8页
Chinese Journal of Surgical Oncology
关键词
胆囊癌
靶向治疗
信号通路
潜在靶点
临床研究
Gallbladder cancer
Targeted therapy
Signaling pathway
Potential target
Clinical research
